The Serotonin Reuptake Inhibitor Sertraline Reduces Excessive Alcohol Consumption in Nonhuman Primates: Effect of Stress J

Total Page:16

File Type:pdf, Size:1020Kb

The Serotonin Reuptake Inhibitor Sertraline Reduces Excessive Alcohol Consumption in Nonhuman Primates: Effect of Stress J The Serotonin Reuptake Inhibitor Sertraline Reduces Excessive Alcohol Consumption in Nonhuman Primates: Effect of Stress J. Higley, Ph.D., M. Hasert, M.S., S. Suomi, Ph.D., and M. Linnoila, M.D., Ph.D. Many monkeys that are reared without adult influence, when the stress was repeated, alcohol consumption fell with only peers, voluntarily consume alcohol in amounts below baseline and placebo levels. Sertraline treatment was producing intoxication on a relatively regular basis. Using ineffective in reducing consumption during the stressful a cross-over design, eight adolescent, peer-reared rhesus period of home-cage reunion, a period characterized by high monkeys were allowed unfettered access to an 8.4% ethanol levels of aggressive behavior. Behaviorally, sertraline solution and treated with 20 mg/kg/24 h of sertraline reduced aggression and anxiety-like self-directed behaviors. during three phases: home-cage, social separation, and Our findings provide evidence that sertraline may be an reunion with cage-mates. Although there was no immediate effective pharmacological treatment for excessive alcohol effect, sertraline reduced alcohol consumption beginning the consumption and aggression. On the other hand, stress second week of home-cage treatment, but only in subjects during treatment may reduce sertraline’s effectiveness as a that consumed large amounts of alcohol. Initially, the social treatment for excessive alcohol consumption. separation stress caused the sertraline-treated subjects’ [Neuropsychopharmacology 18:431–443, 1998] alcohol consumption rates to return to baseline levels, but Published by Elsevier Science Inc. KEY WORDS: Alcoholism and alcohol abuse; Primate; at risk for or who exhibit early onset alcohol abuse and Sertraline; Serotonin; Aggression; Stress alcoholism (for recent reviews see LeMarquand et al. 1994a; Litten et al. 1996; Pettinati 1996). Some recent A large number of preclinical studies have reported studies show that selective serotonin reuptake inhibi- high rates of alcohol consumption among animals with tors (SSRIs) are promising as adjunctive pharmacologi- reduced central nervous system (CNS) serotonin func- cal treatment for maintenance of abstinence (see LeMar- tioning (for reviews, see Sellers et al. 1992; LeMarquand quand et al. 1994b). Preclinical studies with rodents et al. 1994b). Among humans, clinical studies show evi- show that the SSRIs reduce alcohol consumption dence of reduced CNS serotonin functioning in subjects (LeMarquand et al. 1994b). Similarly, in a number of small scale studies, SSRIs have shown promise as an ad- junct treatment for alcohol abuse and alcoholism From the Section on Neurochemistry and Neuro-endocrinology, (LeMarquand et al. 1994a; Pettinati 1996). The con- Primate Unit, Laboratory of Clinical Studies, Primate Unit, DICBR, trolled studies conducted by Gorelick (1989) and Kranz- NIAAA (JH, MH, ML), and Laboratory of Comparative Ethology, NICHD (SS), Poolesville, Maryland. ler et al. (1995) showed, however, that fluoxetine was Address correspondence to: Dr. J.D. Higley, Laboratory of Clini- ineffective in promoting maintenance of abstinence cal Studies, DICBR, NIAAA, Section on Neurochemistry and Neu- among treatment-seeking alcoholics. More recently, re- roendocrinology, Primate Unit, Poolesville, MD 20837. Received April 23, 1997; revised September 1, 1997; accepted Sep- searchers used a controlled study to demonstrate that tember 3, 1997. citalopram was efficacious in promoting maintenance NEUROPSYCHOPHARMACOLOGY 1998–VOL. 18, NO. 6 Published by Elsevier Science Inc. 0893-133X/98/$19.00 655 Avenue of the Americas, New York, NY 10010 PII S0893-133X(97)00180-2 432 J. Higley et al. NEUROPSYCHOPHARMACOLOGY 1998–VOL. 18, NO. 6 of abstinence among early-onset, violent male alcohol- jects reared by their mothers (Higley et al. 1994; 1996d). ics thought to have reduced central serotonin function- Because they share biochemical and behavioral similar- ing (Tiihonen et al. 1996). Because of the conflicting re- ities with some types of human alcoholics, and because ports on the efficacy of the SSRIs in the maintenance of they are more likely than normally reared monkeys to abstinence, we decided to investigate sertraline as a po- consume alcohol at rates that produce intoxication, tential treatment for excessive alcohol intake, using a peer-reared monkeys appear to be well suited to evalu- nonhuman primate model with monkeys known to ate pharmacological treatments for excessive consump- have reduced central serotonin functioning (Higley et tion. Based on what is known about peer-only reared al. 1996d,e). Furthermore, we designed the study specif- subjects, we hypothesized that sertraline would reduce ically to examine the role that stress plays in excessive their day-to-day alcohol consumption, particularly dur- alcohol consumption among nonhuman primates and ing nonstressful home-cage interactions. to test the efficacy of sertraline in mitigating the effects Previous studies have suggested that the effect of the of stress on alcohol consumption. SSRIs on alcohol consumption is not uniform across all Until recently, it was widely believed that nonhu- subjects. For example, Balldin and colleagues (Balldin et man primates would not voluntarily consume alcohol al. 1994) found that human subjects with modestly ele- in appreciable quantities (e.g., Mello and Mendelson vated rates of alcohol consumption (below 107 g per 1971; Meisch et al. 1975; Crowley et al. 1983); conse- day, mean consumption 85 g per day) were particularly quently, they were not typically used in research on al- likely to reduce their alcohol consumption after SSRI cohol abuse. More recent studies have shown, however, treatment as compared with subjects with very high that for many species of primates, many (but not all) consumption rates (above 107 g, mean consumption 138 subjects will freely consume alcohol in quantities that g per day). On the other hand, studies show that pri- produce pharmacological effects when an alcohol solu- mates with the lowest CNS serotonin functioning tend tion is palatable (Higley et al. 1991; Higley 1996; Higley to be the highest alcohol consumers (Higley et al. 1991, and Linnoila 1997). Within some species, such as rhesus 1996e), and alcoholics and sons of alcoholics also show macaques and other Old World primate species, some low CNS serotonin functioning (Ballenger et al. 1979; individual subjects will routinely consume sufficient Banki 1981; Borg et al. 1985). It is therefore not unrea- quantities of alcohol to produce blood levels exceeding sonable to predict that the subjects with the highest con- the limits of legal intoxication for most states in the sumption patterns would benefit most from SSRI treat- United States, and at times drink amounts that produce ment. Thus, we further hypothesized that sertraline stupor and unconsciousness (Erwin et al. 1979; Ervin et treatment would be most effective in those subjects al. 1990; Higley et al. 1991). Most rhesus monkeys are whose consumption rates were high and whose con- modest consumers, however, with only 15–20% consum- sumption patterns were less restrained. ing alcohol in daily quantities that produce intoxication. Studies have also shown that anxiety-like behaviors More recent studies of alcohol consumption in non- and high levels of stress are positively correlated with human primates have investigated variables that are as- the level of alcohol consumption (Kraemer and McKin- sociated with high alcohol consumption. Results from ney 1985; Higley et al. 1991, 1996e). Social separation these studies parallel investigations in humans showing stress (removal and isolation of subjects from their so- that low CSF 5-hydroxyindoleacetic acid (5-HIAA) and cial group) increases alcohol consumption, even among 3-methoxy-4-hydroxyphenylgycol (MHPG) are corre- subjects not particularly prone to overconsume alcohol lated with excessive alcohol consumption (Higley et al. (Kraemer and McKinney 1985; Higley et al. 1991). Among 1991; 1996e). Another factor that increases alcohol con- humans who receive antidepressants for the treatment sumption in nonhuman primates such as rhesus of unipolar depression, some studies show that stress macaques involves an early rearing history in which increases probability of relapse (Belsher and Costello young subjects are raised in social groups that do not 1989; Leverich et al. 1990). Some studies also show that contain adults (peer-only reared subjects—Higley et al. stressful conditions increase the probability of relapse 1991, 1996e). Subjects reared early in life with only among abstinent alcoholics (Brown et al. 1990), and in- same-aged peers, for example, are about twice as likely dividuals who relapse after treatment are more likely to to consume alcohol at rates that produce daily intoxica- report high levels of state and trait anxiety (Brown et al. tion as subjects reared early in life by their parents (Hig- 1991). Such findings suggest that stress may attenuate ley et al. 1991, 1996e). Peer-only reared subjects also the effect of a pharmacological treatment and led us to show low concentrations of CSF 5-HIAA and MHPG test the effectiveness of sertraline in peer-reared mon- (Higley et al. 1991, 1996d,e). Like human subjects with keys under both baseline and stressful conditions. Spe- low CSF 5-HIAA concentrations when peer-only reared cifically, we hypothesized that sertraline would reduce subjects mature to adulthood, they are excessively ag- alcohol consumption during baseline
Recommended publications
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Clinical Inquiries
    CLINICAL INQUIRIES F ROM THE F AMILY P RACTICE I NQUIRIES N ETWORK What is the best way to evaluate patients with acute diarrhea. Using retrospective 6 acute diarrhea? reviews, Bauer and colleagues developed a pre- diction rule for cases of infectious diarrhea. The “modified 3-day rule” recommends stool cultures EVIDENCE-BASED ANSWER Limited evidence for patients with diarrhea beginning more than 3 delineates the relative probabilities of causes of acute days after hospitalization only when they fall into 1 diarrhea, typically defined as a diarrheal disease last- of the following groups: patients older than 65 ing 14 days or fewer, in the developed world. Viruses years with permanently altered organ function, (rotavirus, Norwalk, and other enteric viruses) are those with HIV or neutropenia, those hospitalized responsible for most cases. Stool culture helps to iden- during suspected nosocomial outbreaks, and those tify bacterial causes (Salmonella, Shigella, enterotoxic suspected of nondiarrheal manifestations of enteric Escherichia coli), especially in patients with fever and infection.6 When the modified rule was applied bloody stool. A modified 3-day rule (eg, performing prospectively, only 2 cases were missed. Both only Clostridium difficile toxin tests on low-risk patients were at risk for immunosuppression, patients who have been hospitalized for 3 or more although they did not strictly meet the modified cri- days) leads to a more rational use of stool cultures teria. Neither required treatment.6 without missing cases of clinically significant disease. (Grade of recommendation: D, based on limited stud- RECOMMENDATIONS FROM OTHERS The ies, reliance on expert opinion, and consensus.) Infectious Diseases Society of America’s practice guidelines for the evaluation and treatment of acute EVIDENCE SUMMARY More than 2 million cases diarrhea recommends that stool culture for bacteria of infectious diarrhea are documented in the United (including enterotoxic E coli) should be considered States annually.
    [Show full text]
  • AMERSA) 125 Whipple Street, 3Rd Floor Providence, Rhode Island 02908
    Strategic Plan for Interdisciplinary Faculty Development: Arming the Nation’s Health Professional Workforce for a New Approach to Substance Use Disorders Edited by MARY R. HAACK, PHD, RN, FAAN HOOVER ADGER, JR., MD, MPH Association for Medical Education and Research in Substance Abuse (AMERSA) 125 Whipple Street, 3rd Floor Providence, Rhode Island 02908 For more information: AMERSA Telephone: 401-349-0000 Fax: 877-418-8769 Web Sites: www.amersa.org and www.projectmainstream.net This publication has been produced by the Association for Medical Education and Research in Substance Abuse under a Cooperative Agreement (HRSA-#U78HP00001) with the Bureau of Health Professions, Health Resources and Services Administration (HRSA), in collaboration with the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (SAMHSA). The conclusions and opinions expressed herein are those of the authors and do not necessarily represent the views and policies of HRSA or of SAMHSA. September 2002 TABLE OF CONTENTS Table of Contents............................................................................................................................................................iii Contributors ....................................................................................................................................................................v Acknowledgments .........................................................................................................................................................vii
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma Et Al
    US 20100081713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma et al. (43) Pub. Date: Apr. 1, 2010 (54) COMPOSITIONS AND METHODS FOR (22) Filed: Mar. 18, 2009 TREATINGVIRAL INFECTIONS Related U.S. Application Data (75) Inventors: Geeta Sharma, Singapore (SG); (60) Provisional application No. 61/069,917, filed on Mar. Ralf Altmeyer, Singapore (SG); 19, 2008. Vishal Pendharker, Singapore (SG); Yu Chen, Singapore (SG); Publication Classification Michael Foley, Chestnut Hill, MA (51) Int. Cl. (US) A63L/35 (2006.01) A6II 3L/25 (2006.01) Correspondence Address: A63L/35 (2006.01) Gearhart Law LLC A6II 3/13 (2006.01) 4 Femdale Avenue A6IP3L/2 (2006.01) Chatham, NJ 07928 (US) (52) U.S. Cl. .......... 514/459; 514/529; 514/647: 514/662 (73) Assignee: CombinatoRx, (Singapore) Pte. (57) ABSTRACT Ltd. The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infec (21) Appl. No.: 12/406,716 tion caused by an influenza virus). Patent Application Publication Apr. 1, 2010 Sheet 1 of 2 US 2010/0081713 A1 ------ 80 r -0. Vehicle 0.5% HPMC g - - Sertraline-30mg/kg/day - £ 60 “A Sertraline-100mg/kg/day/kg/day i -v. Oseltamivir-30mg/kg/day ...i -0. Oseltamivir-100mg/kg/day -0. (Sertraline 30mg/kg+ . 40 Prednisolone 0.1 mg/Kg) Figure 1 Patent Application Publication Apr. 1, 2010 Sheet 2 of 2 US 2010/0081713 A1 100 468OOO 2 O Wehicle Sentraline 10 mg/kg Sentraline 30mg/kg Setraline 100mg/kg Figure 2 US 2010/008 1713 A1 Apr.
    [Show full text]
  • Substance Abuse
    \1\A-10/PSA/93.10 ORIGINAL: ENGUSH DISTR.: GENERAL PROGRAMME ON SUBSTANCE ABUSE Approaches to Treatment of Substance Abuse WORLD HEALTH ORGANIZATION ABSTRACf The aim of this report is to provide an updated description of different methods used around the world to treat health problems associated with substance use. The scope of treatment approaches currently practised around the world is wide, ranging from traditional healing practices via mutual self-help groups, psychological/behavioural treatment to pharmacological treatment. Also included is a chapter on the generalist responses to alcohol and other drug problems and a chapter on the concept of harm minimization. Another aspect is a chapter on specific descriptors, which distinguishes different treatments from one another and provides economic means of describing them. Social and structural extra-treatment factors influencing the treatment process are also a subject described in this report. ©World Health Organization, 1993 This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced and translated in part or in whole, but not for sale nor for use in conjunction with commercial purposes. The views expressed in documents by named authors are solely the responsibility of those authors. ii CONTENTS page Acknowledgements . v Introduction . 1 I. Descriptors of Treatments . 3 11. Factors Influencing Treatment . 31 Ill. Generalist Responses to Alcohol and other Drug Problems . 53 IV. Pharmacological Treatment of Dependence on Alcohol and other Drugs: An Overview . 75 V. Psychological, Behavioural and Psychodynamic Treatments for Substance Abuse . 103 VI.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • TIP 28: Naltrexone and Alcoholism Treatment 28: Treatment Improvement Protocol (TIP) Series 28
    TIP 28: Naltrexone And Alcoholism Treatment 28: Treatment Improvement Protocol (TIP) Series 28 A51510 Stephanie O'Malley, Ph.D. Consensus Panel Chair U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment Rockwall II, 5600 Fishers Lane Rockville, MD 20857 Disclaimer This publication is part of the Substance Abuse Prevention and Treatment Block Grant technical assistance program. All material appearing in this volume except that taken directly from copyrighted sources is in the public domain and may be reproduced or copied without permission from the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Substance Abuse Treatment (CSAT) or the authors. Citation of the source is appreciated. This publication was written under contract number 270-95-0013 with The CDM Group, Inc. (CDM). Sandra Clunies, M.S., I.C.A.D.C., served as the CSAT government project officer. Rose M. Urban, M.S.W., J.D., C.S.A.C., served as the CDM TIPs project director. Other CDM TIPs personnel included Mark A. Meschter, senior editor/writer; Y-Lang Nguyen, editorial assistant; Raquel Ingraham, M.S., assistant project manager; Mary Smolenski, Ed.D., C.R.N.P., former project director; and MaryLou Leonard, former project manager. Special thanks go to consulting writers Suchitra Krishnan-Sarin, Ph.D., and Elyse Eisenberg, M.D., for their contributions to this document. The opinions expressed herein are the views of the Consensus Panel members and do not reflect the official position of CSAT, SAMHSA, or the U.S.
    [Show full text]
  • CUSTOMS TARIFF - SCHEDULE 99 - I
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2016 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • WO 2007/061529 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 31 May 2007 (31.05.2007) PCT WO 2007/061529 Al (51) International Patent Classification: GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, A61K 9/14 (2006.01) KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MY, MZ, (21) International Application Number: NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, PCT/US2006/040197 SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (22) International Filing Date: 13 October 2006 (13.10.2006) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (26) Publication Language: English ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV,MC, NL, PL, PT, (30) Priority Data: RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, 11/282,507 18 November 2005 (18.1 1.2005) US GN, GQ, GW, ML, MR, NE, SN, TD, TG). (71) Applicant (for all designated States except US): SCI- Declarations under Rule 4.17: DOSE PHARMA INC.
    [Show full text]
  • Invited Review Pharmacotherapy of Alcoholism: Gaps in Knowledge And
    Alcohol & Alcoholism Vol. 35, No. 6, pp. 537–547, 2000 INVITED REVIEW PHARMACOTHERAPY OF ALCOHOLISM: GAPS IN KNOWLEDGE AND OPPORTUNITIES FOR RESEARCH HENRY R. KRANZLER* Alcohol Research Center, Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT 06030, USA (Received 8 December 1999; in revised form 11 June 2000) Abstract — During the past decade, renewed interest in medications to prevent relapse in alcoholics has yielded a number of promising candidates. Although two of these medications, naltrexone and acamprosate, are currently in clinical use in a number of countries, overall, their effectiveness appears to be limited. Disulfiram, the deterrent medication that was approved 50 years ago for the treatment of alcoholism, has not consistently been shown to be efficacious. However, since inadequate dosing and other modifiable factors may limit its deterrent effects, the identification of a more potent metabolite of disulfiram appears to warrant further evaluation. Studies of serotonergic agonists for treatment of alcoholism have also yielded inconsistent results. There is evidence, however, that subgroups of alcoholics may respond well to such medications, suggesting that treatment matching may enhance their efficacy. In addition, nalmefene, a compound with effects similar to naltrexone, as well as a sustained release formulation of naltrexone, may enhance the beneficial effects of opioid antagonist therapy. Despite these developments, much remains to be learned about the pharmacotherapy of alcoholism. The ongoing development and evaluation of novel medications should be given a high priority. However, such basic issues as the optimal dosing strategy and duration of treatment for existing therapies are not known. Similarly, combination therapy, involving either multiple medications or the combination of medication with specific psychotherapies, has not been well studied.
    [Show full text]
  • How Effective Are Pharmacologic Agents for Alcoholism?
    June 2002 (Vol. 51, No. 6) CLINICAL INQUIRIES FROM THE FA M I L Y PRACTICE INQUIRIES NETWORK How effective are pharmacologic agents for alcoholism? R. Randy Hunt, DO, FAAFP OUHSC–Tulsa, Department of Family Medicine Literature search performed by Joan Nashelsky, MLS. EVIDENCE-BASED ANSWER Naltrexone (ReVia) and nalmefene (Revex) are the most effective agents for treating alcoholism. Acamprosate is effective but not available in the United States. Serotonergic agents, selective serotonin reuptake inhibitors (SSRIs), and lithium work best in patients with alcoholism and comorbid depression, anxiety, or bipolar disorder. Disulfiram (Antabuse) decreases drink frequency, but is no better than placebo for other outcomes. Greater effectiveness is achieved when pharmacologic agents are combined with either counseling or Alcoholics Anonymous programs. (Grade of recommendation: B, based on multiple randomized controlled studies with short and incomplete follow-up of patients.) EVIDENCE SUMMARY Naltrexone (50 mg qd), nalmefene (10–80 mg qd), and acamprosate (dose based on patient weight) are all superior to placebo and other agents such as the SSRIs, disulfiram, and serotonergic agents in reducing relapse rates and the phenomena of craving and in increasing abstinence rates.1-6 For example, naltrexone reduces relapse rates by one half to two thirds.4,6 However, these outcomes apply only to patients who completed the study protocol; noncompleters accounted for up to more than 50% of study participants. When compared with placebo, nalmefene taken for
    [Show full text]
  • 2 11/ 7 361Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date - l 6 June 20ll (I6.06.20ll) 2 11/ 7 361 Al (51) International Patent Classification: (74) Agents: KINNAIRD, James et al; 90 High Holborn, A61K 9/14 (2006.01) A61K 9/51 (2006.01) London, Greater London WC1V 6XX (GB). A61K 9/16 (2006.01) A61K 31/4045 (2006.01) (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, PCT/GB2010/052053 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 8 December 2010 (08.12.2010) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (25) Filing Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (30) Priority Data: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 0921481 .8 8 December 2009 (08.12.2009) GB (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): VEC- kind of regional protection available): ARIPO (BW, GH, TURA LIMITED [—/GB]; 1 Prospect West, Chippen GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ham Wiltshire SN14 6FH (GB).
    [Show full text]